News
GERN
2.560
-8.24%
-0.230
Interesting GERN Put And Call Options For March 21st
NASDAQ · 5d ago
Weekly Report: what happened at GERN last week (0203-0207)?
Weekly Report · 5d ago
Largest borrow rate increases among liquid names
TipRanks · 02/05 13:45
Those who invested in Geron (NASDAQ:GERN) three years ago are up 188%
Simply Wall St · 02/05 12:09
Is Geron A Buyout Target? The RPRX Deal Says No
Seeking Alpha · 02/04 06:56
After Hours Most Active for Feb 3, 2025 : SNAP, PLTR, NVDA, T, ALTM, GERN, INTC, AAPL, PFE, BAC, LUMN, VCIT
NASDAQ · 02/03 21:29
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Seeking Alpha · 02/03 15:46
Press Release: Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Dow Jones · 02/03 14:03
Weekly Report: what happened at GERN last week (0127-0131)?
Weekly Report · 02/03 09:00
Strategic IP Advancements and Revenue Projections Bolster Geron’s Buy Recommendation
TipRanks · 01/30 08:37
Geron Inc.: Strong Q4 Performance and Promising Growth Outlook Support Buy Rating
TipRanks · 01/29 11:45
Weekly Report: what happened at GERN last week (0120-0124)?
Weekly Report · 01/27 09:00
GERON REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/21 21:30
Weekly Report: what happened at GERN last week (0113-0117)?
Weekly Report · 01/20 09:00
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Seeking Alpha · 01/16 18:46
Geron (GERN) Receives a Buy from Barclays
TipRanks · 01/15 12:15
Strong Growth and Strategic Financial Management Bolster Buy Rating for Geron’s Promising Rytelo Drug
TipRanks · 01/15 07:11
Geron’s Promising Market Growth: Strong Sales Performance and Optimistic Financial Guidance
TipRanks · 01/14 01:09
Geron updates on Q4 revenue from U.S. sales of RYTELO
Seeking Alpha · 01/13 17:42
Geron Price Target Raised to $7.00/Share From $6.00 by Needham
Dow Jones · 01/13 15:48
More
Webull provides a variety of real-time GERN stock news. You can receive the latest news about Geron Corp through multiple platforms. This information may help you make smarter investment decisions.
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.